| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 7, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that Perrigo has begun shipping Levocetirizine...
-
Nov 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for...
-
Nov 1, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl...
-
Oct 27, 2011-- Fiscal first quarter revenue from continuing operations increased $84 million, or 13%, to a record $725 million
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) today announced results for its first quarter ended September 24, 2011. Perrigo's Chairman and CEO Joseph...
-
Oct 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on December...
-
Oct 19, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned...
-
Oct 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...
-
Oct 14, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2012 on Thursday, October 27,...
-
Oct 6, 2011
Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated...
-
Oct 4, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown and Senior Management will meet with analysts on Wednesday, October 5,...
-
Sep 23, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa and Senior Management will meet with analysts on...
-
Aug 30, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its...
-
Aug 16, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced it expects to issue $350 million of notes in its fiscal second quarter pursuant to its existing...
-
Aug 16, 2011-- Full-year revenue from continuing operations increased $487 million, or 21%, to a record $2.76 billion.
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 25, 2011. Perrigo's Chairman and CEO...
-
Aug 11, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...
-
Aug 2, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its fourth quarter fiscal 2011 on Tuesday, August 16 ,...
-
Jul 26, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has closed the acquisition of Paddock...
-
Jul 21, 2011
The Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market...
-
Jun 29, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize the regulatory approvals necessary to complete the...
-
Jun 15, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories...
-
Jun 3, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Goldman Sachs 32nd Annual Global...
-
May 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the...
-
May 16, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 10, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by...
-
May 3, 2011-- Fiscal third quarter revenue from continuing operations increased $154 million, or 29%, to $692 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011. Perrigo's Chairman and CEO Joseph C. Papa...